25th Annual Biotech in Europe Forum

Sachs Associates would like to say that we have enjoyed hosting you in person and virtually and thank those who participated in our Sachs Autumn Life Sciences Week, which incorporated the 11th Annual HealthTech Investment Forum (#Sachs_HTIF) and the 24th Annual Biotech in Europe Forum (#Sachs_BEF). A special thank you goes to the excellent lineup of sponsors, chairs, panellists, and presenters who made such a broad and interesting programme possible and to those who participated in person and during the virtual week.

The Life Sciences Week has proven to be successful in supporting our community with 589 delegates from 32 countries and over 2500 in-person & online meetings completed.

Publicly available recordings of the sessions and presentations that took place during the event will be added once the event portal closes (after the 25th of October) on the SachsTV YouTube channel.

We are looking forward to welcoming you again at our future events!

Keynote Speakers Included:

• Gregory Rall, Deputy Head, Innovation & Technology, InvestHK
• Laura Lane, VP, Lilly Ventures – Europe Head External Innovation, Eli Lilly and Company
• Lukas Engelberger, State Councillor, Department of Public Health, Canton of Basel-Stadt
• Fireside Discussion: „How I Took a European Biotech to a Billion-Dollar Exit“ With: Renée Aguiar-Lucander, CEO, Calliditas Therapeutics AB

Confirmed Speakers & Chairs Included:

• Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG
• Alex Blyth, CEO, LIfT BioSciences Ltd.
• Anders Bue Klein, Co-Founder & CEO, Ousia Pharma ApS
• Antoine Boulanger, Principal, Forbion
• Antti Vuolanto, CEO, Herantis Pharma Plc
• Aram Mangasarian, CEO, TME Pharma
• Asun Monfort, Investment Advisor, HBM Partners AG
• Berthold Hinzen, Global Head BD&L Transactions Immunology, Novartis AG
• Carlos Buesa, Founder & CEO, Oryzon Genomics, S.A.
• Christoph Korpus, Director Global Business Development & Licensing Oncology, Merck KGaA, Darmstadt, Germany
• Cindy Daniel, Head of Unit – Life Sciences & Healthcare – Equity Investments, European Investment Fund
• Darren Ji, Co-Founder, Chairman & CEO, Elpiscience Biopharmaceuticals Co. Ltd.
• Dimitrios Weedon-Topalopoulos, Managing Director, OrbiMed Advisors LLC
• Dragan Grabulovski, Founder & CEO, Grabulovski Consulting Services GmbH
• Edward van Wezel, Managing Partner, BioGeneration Ventures
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
• Federico Bolognani, Chief Medical Officer, IAMA Therapeutics S.r.l.
• François Thomas, Operating Partner, Quadrille Capital
• Frank Grams, Chief Commercial Officer, Partex N.V.
• Gregory Rall,  Deputy Head, Innovation & Technology, InvestHK
• Helen Chen, Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner, L.E.K. Consulting
• Hubert Birner, Managing Partner, TVM Capital Life Science
• Isabella Schidrich, Senior Managing Director, Listings EMEA, Nasdaq
• Jeremy Griggs, Executive Director, Search & Evaluation, GSK
• Jesus Baena, BD&L Transactions Director, Novartis AG
• Joachim Vogt, Director Search & Evaluation International, AbbVie, Inc.
• Josua Jordi, Discovery Area Lead in Metabolism, F. Hoffmann-La Roche AG
• Katharina Kreymborg, SVP, Curie.Bio
• Keld Flintholm Jørgensen, SVP & CBO, H. Lundbeck A/S
• Kelly Curtin, Managing Director, Stifel
• Konstantin Petropoulos, CBO & Managing Director, Secarna Pharmaceuticals GmbH & Co. KG
• Kristian Tryggvason, Founder & CEO, Alder Therapeutics AB
• Laurent Jacqueroud, BD & Investment Director, Cumulus Oncology
• Louise S. Dalbøge, Chief Science Officer, Gubra A/S
• Lynn Durham, Founder & CEO, STALICLA SA
• Magne Stoknes, Principal, Novo Holdings A/S
• Marianne Uteng, Managing Director, Novartis Venture Fund
• Marie Schroeder, Vice President, Novo Holdings A/S
• Marina Udier, CEO, Nouscom AG
• Matthieu Coutet, Partner, Sofinnova Partners
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Hübner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC
• Neil Anderson, Head of Science2Medicine iNNvest, Novo Nordisk A/S
• Nigel Sheail, Venture Partner, Versant Ventures
• Olav Zilian, Senior Financial Analyst, Pictet & Cie
• Patrick Schwab, Senior Director, AI & Machine Learning, GSK
• Paul Bravetti, CEO, Brenus Pharma
• Paul Hermant, Partner, Bird & Bird LLP
• Peter Braun, CEO, TargImmune Therapeutics AG
• Rainer Strohmenger, Managing Partner, Wellington Partners
• Renée Aguiar-Lucander, CEO, Calliditas Therapeutics AB
• Rianne Ellenbroek, Principal, BioGeneration Ventures
• Ricardo Pacheco, Strategic Partnering, BD& Director, Insilico Medicine
• Richard Ward, Executive Director, Search & Evaluation, AstraZeneca
• Rupert Haynes, CEO, Avata Biosciences
• Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
• Sandra von Meier, Head Business Development & Licensing, Debiopharm International SA
• Sanja Tomovska, Co-Founder & CEO, Quant Biomarkers AG
• Sarah Holland, President of Swiss Healthcare Licensing Group & CBO, Cureteq AG
• Seth Goldblum, SVP – Corporate Development, Cullgen Inc.
• Shelley Margetson, Managing Partner, V-Bio Ventures B
• Stephan Emmerth, Director, BaseLaunch
• Stephane Degove, CEO, Atamyo Therapeutics SAS
• Stephanie Léouzon, Managing Director & Vice Chair of European Healthcare Investment Banking, Stifel
• Tamas Schweighoffer, Co-Founding Partner, Forty51 Ventures
• Victoria English, Co-Founder & Editor, Evernow Publishing Ltd, publisher of MedNous
• Ximing Ding, Investment Manager, Pureos Bioventures